MET MetLife, Inc. - Fundamental Analysis

MetLife's deterministic health scores indicate moderate financial stability with a Piotroski F-Score of 4/9, signaling borderline strength, while the absence of an Altman Z-Score prevents a full distress risk assessment. The stock trades above the Graham Number of $72.34 at $76.77, suggesting slight overvaluation on a defensive basis, though forward P/E of 7.77 implies strong earnings recovery expectations. Despite solid ROE of 12.80% and a healthy dividend yield of 2.91%, recent earnings deterioration, negative revenue growth, and weak analyst sentiment—evidenced by consistent misses and a bearish technical trend—offset value appeal. Sector comparisons show MetLife is cheaper than average but lags in growth and profitability metrics.